Preventive measures and new pharmacological approaches of calcium and phosphate disorders

Contributions to Nephrology

Volumn 161, Issue , 2008, Pages 234-239

  Cozzolino, M ^a   Galassi, A ^a   Pasho, S ^a   Fallabrino, G ^a   Gallieni, M ^a   Brancaccio, D ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CINACALCET; LANTHANUM; LANTHANUM CARBONATE; NAPHTHALENE DERIVATIVE; PHOSPHATE; POLYAMINE; SEVELAMER; VITAMIN D;

CHRONIC DISEASE; HUMAN; KIDNEY DISEASE; METABOLISM; RENAL REPLACEMENT THERAPY; REVIEW; SECONDARY HYPERPARATHYROIDISM;

CALCIUM; CHRONIC DISEASE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY DISEASES; LANTHANUM; NAPHTHALENES; PHOSPHATES; POLYAMINES; RENAL DIALYSIS; VITAMIN D;

EID: 48049093538     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000130696     Document Type: Conference Paper

References (17)

1. Cozzolino M, Brancaccio D, Gallieni M, et al: Pathogenesis of parathyroid hyperplasia in renal failure. J Nephrol 2005;18:5-8.
2. Denda M, Finch J, Slatopolsky E: Phosphorus accelerated the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure. Am J Kidney Dis 1996;28:596-602.
3. Brown EM: Calcium receptor and regulation of parathyroid hormone secretion. Rev Endocr Metab Disord 2000;1:307-315.
4. 3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 1989;35:1049-1056.
5. Slatopolsky E, Weerts C, Lopez-Hilker S, et al: Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 1986;315:157-161.
6. Block GA, Klassen PS, Lazarus JM, et al: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-2218.
7. Cozzolino M, Brancaccio D, Gallieni M, Slatopolsky E: Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 2005;68:429-436.
8. Brancaccio D, Cozzolino M: The mechanism of calcium deposition in soft tissues. Contrib Nephrol. Basel, Karger, 2005, vol 149, pp 279-286.
9. Cozzolino M, Staniforth ME, Liapis H, et al: Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int 2003;64:1653-1661.
10. Chertow GM, Burke SK, Lazarus JM, et al: Poly[allylamine hydrochloride] (Renagel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997;29:66-71.
11. Suki WN, Zabenh R, Cangiano JL, et al: Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72:1130-1137.
12. Cozzolino M, Brancaccio D: Hyperphosphatemia in dialysis patients: the therapeutic role of lanthanum carbonate. Int J Artif Organs 2007;30:293-300.
13. Finn WF, Joy MS, Hladik G; Lanthanum Study Group: Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol 2004;62:193-201.
14. Sprague SM, Llach F, Amdhal M, et al: Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003;63:1483-1490.
15. Teng M, Wolf M, Lowrie E, et al: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446-456.
16. Mizobuchi M, Finch JL, Martin DR, Slatopolsky E, Cardus A, Panizo S, Parisi E, et al: Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 2007;72:709-715.
17. Block GA, Martin KJ, de Francisco ALM: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516-1525.